Journal of clinical and translational research最新文献

英文中文

Effectiveness of health education interventions in patients with fibromyalgia syndrome: an umbrella review 健康教育干预对纤维肌痛综合征患者的有效性:综述

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202306.23-00108

引用次数: 0

Enhancing clinical and translational research in Africa: a comprehensive exploration of challenges and opportunities for advancement 加强非洲的临床和转化研究:全面探索进步的挑战和机遇

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202305.23-00079

引用次数: 0

Frequency of consumption of green leafy vegetables and prevalence of hyperglycaemia in Ankole and Teso sub-regions of Uganda 乌干达安科勒和特索次区域绿叶蔬菜消费频率和高血糖患病率

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202306.23-00096

Background: Type 2 diabetes-related hyperglyceamia is a global health problem, with developing countries like Uganda currently experiencing substantial rises in the metabolic disorder. Current hyperglyceamia therapies can bring a patient to glycemic target; however, they are costly and have other limitations. Vegetable extracts have health-protecting effects and contain thousands of components with putative hypoglycemic effects, rendering them a cheaper alternative towards prevention and management of hyperglyceamia. Aim: The goal of this study was to determine the frequency and patterns of consumption of green leafy vegetables, and their relationship with the prevalence of hyperglyceamia in two sub-regions of Uganda. Methods: A cross sectional household survey was conducted in Ankole and Teso sub-regions of Uganda. Using a questionnaire for both face-to-face interviews and focus group discussions (FGDs), the frequently eaten vegetables and their consumption were documented, and fasting blood glucose (FBG) levels measured to determine the prevalence of hyperglyceamia. Results: The most frequently eaten vegetables in both sub-regions were Amaranthus species. Brassica species, Curcubita maxima L. , Solanum nigrum s.l. and Phaseolus vulgaris L. were eaten mostly in Ankole sub-region while Vigna unguiculata (L.) Walp. and Hibiscus sabdariffa L. were eaten mostly in Teso sub-region. In Ankole sub-region, the vegetables were steamed, while boiling and adding peanut/simsim butter was preferred in Teso sub-region. Consumption of leafy vegetables was higher in Teso sub-region than in Ankole sub-region. The overall prevalence of hyperglyceamia was 29.15%; it was higher in Ankole at 35.5% and lower in Teso at 19.5% (95% CI: 0.27-0.69). Conclusion: The difference in prevalence of hyperglycaemia is relatively high in these sub-regions. Consumption of different leafy vegetable species and their various preparation methods likely contributes to this prevalence; however, factors like phytochemical constituents

{"title":"Frequency of consumption of green leafy vegetables and prevalence of hyperglycaemia in Ankole and Teso sub-regions of Uganda","authors":"","doi":"10.18053/jctres.09.202306.23-00096","DOIUrl":"https://doi.org/10.18053/jctres.09.202306.23-00096","url":null,"abstract":"Background: Type 2 diabetes-related hyperglyceamia is a global health problem, with developing countries like Uganda currently experiencing substantial rises in the metabolic disorder. Current hyperglyceamia therapies can bring a patient to glycemic target; however, they are costly and have other limitations. Vegetable extracts have health-protecting effects and contain thousands of components with putative hypoglycemic effects, rendering them a cheaper alternative towards prevention and management of hyperglyceamia. Aim: The goal of this study was to determine the frequency and patterns of consumption of green leafy vegetables, and their relationship with the prevalence of hyperglyceamia in two sub-regions of Uganda. Methods: A cross sectional household survey was conducted in Ankole and Teso sub-regions of Uganda. Using a questionnaire for both face-to-face interviews and focus group discussions (FGDs), the frequently eaten vegetables and their consumption were documented, and fasting blood glucose (FBG) levels measured to determine the prevalence of hyperglyceamia. Results: The most frequently eaten vegetables in both sub-regions were Amaranthus species. Brassica species, Curcubita maxima L. , Solanum nigrum s.l. and Phaseolus vulgaris L. were eaten mostly in Ankole sub-region while Vigna unguiculata (L.) Walp. and Hibiscus sabdariffa L. were eaten mostly in Teso sub-region. In Ankole sub-region, the vegetables were steamed, while boiling and adding peanut/simsim butter was preferred in Teso sub-region. Consumption of leafy vegetables was higher in Teso sub-region than in Ankole sub-region. The overall prevalence of hyperglyceamia was 29.15%; it was higher in Ankole at 35.5% and lower in Teso at 19.5% (95% CI: 0.27-0.69). Conclusion: The difference in prevalence of hyperglycaemia is relatively high in these sub-regions. Consumption of different leafy vegetable species and their various preparation methods likely contributes to this prevalence; however, factors like phytochemical constituents","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135611280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of bronchodilator response between Dosivent® and Aerochamber Plus® Flow-Vu® chambers in patients with bronchial hyperreactivity Dosivent®与Aerochamber Plus®Flow-Vu®支气管扩张剂对支气管高反应性患者反应的比较

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202305.23-00081

Background: Aerochambers are used for the administration of inhaled drugs. Dosivent ® is a previously unstudied chamber. This study aimed to validate the Dosivent ® chamber against the widely used Aerochamber Plus ® Flow-Vu ® . Methods: We conducted a non-randomized, open-label, cross-over-controlled, and clinical trial (NCT05821868) in 50 patients with a known positive bronchodilator test. Bronchodilator washout was performed according to standard recommendations. Fifteen minutes after the administration of 400 µ g of salbutamol with either chamber, the changes in forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) were measured. The agreement was measured by the intraclass correlation coefficient and Bland–Altman graphical analysis. Participants’ satisfaction with the chamber was assessed with the FSI-10 questionnaire. Results: The mean participant age was 58.0 (SD = 18.5) years, half were women, and only 31 (62%) participants had an FEV1/FVC of <0.7. The median increases in FEV1 obtained with the Aerochamber Plus ® Flow-Vu ® and Dosivent ® were 0.28 L (interquartile range [IQR]: 0.21 – 0.38) and 0.29 L (IQR: 0.20 – 0.43), respectively, and the median increases in FVC were 0.29 L (IQR: 0.19 – 0.37) and 0.28 L (IQR: 0.19 – 0.45). The intraclass correlation coefficient for increases in FEV1 was 0.865, and it was 0.820 for increases in FVC. The median FSI-10 questionnaire score was 42 (IQR: 37 – 47) with Aerochamber Plus ® Flow-Vu ® and 44 (39 – 48) with Dosivent ® ( P < 0.001). Conclusions: Our study revealed a strong agreement between salbutamol responses when utilizing both the Dosivent ® and Aerochamber Plus ® Flow-Vu ® chambers. This suggests that these devices are interchangeable and can be effectively employed in routine clinical practice. Relevance for Patients: For patients using inhaled medications, this study provides reassurance regarding the equivalence of the Dosivent ® chamber with the widely used Aerochamber Plus ® Flow-Vu ® . This provides patients with more options for device selection, potentially improving convenience and satisfaction with their inhalation therapy. Patients and healthcare providers can consider the Dosivent ® chamber as a viable alternative, which may positively impact treatment adherence and overall respiratory health management.

{"title":"Comparison of bronchodilator response between Dosivent® and Aerochamber Plus® Flow-Vu® chambers in patients with bronchial hyperreactivity","authors":"","doi":"10.18053/jctres.09.202305.23-00081","DOIUrl":"https://doi.org/10.18053/jctres.09.202305.23-00081","url":null,"abstract":"Background: Aerochambers are used for the administration of inhaled drugs. Dosivent ® is a previously unstudied chamber. This study aimed to validate the Dosivent ® chamber against the widely used Aerochamber Plus ® Flow-Vu ® . Methods: We conducted a non-randomized, open-label, cross-over-controlled, and clinical trial (NCT05821868) in 50 patients with a known positive bronchodilator test. Bronchodilator washout was performed according to standard recommendations. Fifteen minutes after the administration of 400 µ g of salbutamol with either chamber, the changes in forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) were measured. The agreement was measured by the intraclass correlation coefficient and Bland–Altman graphical analysis. Participants’ satisfaction with the chamber was assessed with the FSI-10 questionnaire. Results: The mean participant age was 58.0 (SD = 18.5) years, half were women, and only 31 (62%) participants had an FEV1/FVC of <0.7. The median increases in FEV1 obtained with the Aerochamber Plus ® Flow-Vu ® and Dosivent ® were 0.28 L (interquartile range [IQR]: 0.21 – 0.38) and 0.29 L (IQR: 0.20 – 0.43), respectively, and the median increases in FVC were 0.29 L (IQR: 0.19 – 0.37) and 0.28 L (IQR: 0.19 – 0.45). The intraclass correlation coefficient for increases in FEV1 was 0.865, and it was 0.820 for increases in FVC. The median FSI-10 questionnaire score was 42 (IQR: 37 – 47) with Aerochamber Plus ® Flow-Vu ® and 44 (39 – 48) with Dosivent ® ( P < 0.001). Conclusions: Our study revealed a strong agreement between salbutamol responses when utilizing both the Dosivent ® and Aerochamber Plus ® Flow-Vu ® chambers. This suggests that these devices are interchangeable and can be effectively employed in routine clinical practice. Relevance for Patients: For patients using inhaled medications, this study provides reassurance regarding the equivalence of the Dosivent ® chamber with the widely used Aerochamber Plus ® Flow-Vu ® . This provides patients with more options for device selection, potentially improving convenience and satisfaction with their inhalation therapy. Patients and healthcare providers can consider the Dosivent ® chamber as a viable alternative, which may positively impact treatment adherence and overall respiratory health management.","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135844972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of appendectomy with colorectal cancer: a systematic review and meta-analysis 阑尾切除术与结直肠癌的相关性:一项系统综述和荟萃分析

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202305.23-00090

Background: Appendectomy is a common surgical procedure done worldwide. The appendix is known as a sanctuary for commensal organisms in the gut, and an inflamed appendix may alter the gut microbiome, leading to inflammation and oncogenesis. An association between appendectomy and subsequent colorectal cancer development has been postulated; however, previous studies have differed in study design and results. Method: We performed a systematic review and meta-analysis of studies evaluating the association between appendectomy and colorectal cancer in adults. A literature search of MEDLINE and EMBASE was conducted through September 2022. Search terms included “appendectomy” and “colon cancer” or “rectal cancer” or “colorectal cancer.” Odds ratios and sensitivity analyses were calculated. Result: Of the 541 studies identified in our search, 10 studies met our inclusion criteria. The eight papers that studied the association between appendectomy and colorectal cancer reported no association with the odds ratio (OR) of 1.30 (0.92, 1.83). However, studies on the association of appendectomy and proximal versus distal colon cancer reported a statistically significant increase in proximal colon cancer compared to distal colon cancer OR of 1.48 (1.29, 1.69). Conclusion: Our study demonstrates that appendectomy is associated with the development of proximal colon cancer but not distal colon cancer. Relevance for patients: Patients who have had an appendectomy should be aware of the potentially increased risk for colon cancer. Consequently, they should provide this information during routine clinic visits, especially if they are having gastrointestinal symptoms.

{"title":"Association of appendectomy with colorectal cancer: a systematic review and meta-analysis","authors":"","doi":"10.18053/jctres.09.202305.23-00090","DOIUrl":"https://doi.org/10.18053/jctres.09.202305.23-00090","url":null,"abstract":"Background: Appendectomy is a common surgical procedure done worldwide. The appendix is known as a sanctuary for commensal organisms in the gut, and an inflamed appendix may alter the gut microbiome, leading to inflammation and oncogenesis. An association between appendectomy and subsequent colorectal cancer development has been postulated; however, previous studies have differed in study design and results. Method: We performed a systematic review and meta-analysis of studies evaluating the association between appendectomy and colorectal cancer in adults. A literature search of MEDLINE and EMBASE was conducted through September 2022. Search terms included “appendectomy” and “colon cancer” or “rectal cancer” or “colorectal cancer.” Odds ratios and sensitivity analyses were calculated. Result: Of the 541 studies identified in our search, 10 studies met our inclusion criteria. The eight papers that studied the association between appendectomy and colorectal cancer reported no association with the odds ratio (OR) of 1.30 (0.92, 1.83). However, studies on the association of appendectomy and proximal versus distal colon cancer reported a statistically significant increase in proximal colon cancer compared to distal colon cancer OR of 1.48 (1.29, 1.69). Conclusion: Our study demonstrates that appendectomy is associated with the development of proximal colon cancer but not distal colon cancer. Relevance for patients: Patients who have had an appendectomy should be aware of the potentially increased risk for colon cancer. Consequently, they should provide this information during routine clinic visits, especially if they are having gastrointestinal symptoms.","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135497225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between response to neoadjuvant chemotherapy and survival outcome after radical surgery in patients with yielding pathological T2 and/or N+ urothelial carcinoma 病理T2和/或N+尿路上皮癌患者对新辅助化疗的反应与根治性手术后生存结果的关系

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202306.23-00106

Background and Aim: In early 2022, the use of adjuvant nivolumab for patients with high-risk muscle-invasive urothelial carcinoma was approved in Japan, European countries, and USA based on the positive results of CheckMate 274 trial, which included participants who received neoadjuvant chemotherapy (NAC). Subgroup analyses of CheckMate 274 trial does not report response to neoadjuvant chemotherapy and benefit from adjuvant nivolumab. Herein, we investigated the association between response to NAC and survival outcomes after radical surgery in patients with residual muscle-invasive urothelial carcinoma and/or lymph node disease. Methods: This multicenter retrospective study included a total of 95 NAC-treated patients with yielding pathological (yp) T2  and/or ypN+ urothelial carcinoma on radical surgery specimens. Based on the comparison of clinical T and N category with yp T and N category, the patients were categorized into three groups: down-staged ypT2  (n=14), no-changed ypT2  (n=39), and up-staged ypT2  groups (n=42). Results: There was no significant difference in extra-urinary tract recurrence-free survival, cancer-specific survival, and overall survival after the radical surgery among three groups. Subgroup analysis of a bladder cancer cohort showed a marginal association between better response and longer cancer-specific survival ( P =0.073). Conclusion: Our finding suggested that adjuvant nivolumab should be considered for all the patients with pathological ypT2  or ypN+ urothelial carcinoma regardless of response to NAC. Further research is mandatory in finding predictive factors that serve in decision-making for NAC-treated patients who are likely to benefit from adjuvant nivolumab. Relevance for patients: To develop a decision-making tool for adjuvant nivolumab, we investigated the association between response to neoadjuvant chemotherapy and survival after radical surgery. Further research

{"title":"Association between response to neoadjuvant chemotherapy and survival outcome after radical surgery in patients with yielding pathological T2 and/or N+ urothelial carcinoma","authors":"","doi":"10.18053/jctres.09.202306.23-00106","DOIUrl":"https://doi.org/10.18053/jctres.09.202306.23-00106","url":null,"abstract":"Background and Aim: In early 2022, the use of adjuvant nivolumab for patients with high-risk muscle-invasive urothelial carcinoma was approved in Japan, European countries, and USA based on the positive results of CheckMate 274 trial, which included participants who received neoadjuvant chemotherapy (NAC). Subgroup analyses of CheckMate 274 trial does not report response to neoadjuvant chemotherapy and benefit from adjuvant nivolumab. Herein, we investigated the association between response to NAC and survival outcomes after radical surgery in patients with residual muscle-invasive urothelial carcinoma and/or lymph node disease. Methods: This multicenter retrospective study included a total of 95 NAC-treated patients with yielding pathological (yp) T2  and/or ypN+ urothelial carcinoma on radical surgery specimens. Based on the comparison of clinical T and N category with yp T and N category, the patients were categorized into three groups: down-staged ypT2  (n=14), no-changed ypT2  (n=39), and up-staged ypT2  groups (n=42). Results: There was no significant difference in extra-urinary tract recurrence-free survival, cancer-specific survival, and overall survival after the radical surgery among three groups. Subgroup analysis of a bladder cancer cohort showed a marginal association between better response and longer cancer-specific survival ( P =0.073). Conclusion: Our finding suggested that adjuvant nivolumab should be considered for all the patients with pathological ypT2  or ypN+ urothelial carcinoma regardless of response to NAC. Further research is mandatory in finding predictive factors that serve in decision-making for NAC-treated patients who are likely to benefit from adjuvant nivolumab. Relevance for patients: To develop a decision-making tool for adjuvant nivolumab, we investigated the association between response to neoadjuvant chemotherapy and survival after radical surgery. Further research","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"136 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135611282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in correlations between cervical and distal spinal sagittal alignments in asymptomatic population with aging 在无症状人群中，随着年龄的增长，颈椎和脊柱远端矢状位排列相关性的变化

Journal of clinical and translational research

Pub Date : 2023-01-01 DOI: 10.18053/jctres.09.202305.23-00059

引用次数: 0

Inactivated COVID-19 vaccine triggering hemophagocytic lymphohistiocytosis in an immunocompetent adult - A case report. COVID-19灭活疫苗在免疫功能正常的成人中引发噬血细胞淋巴组织细胞症-1例报告

Journal of clinical and translational research

Pub Date : 2022-03-31 eCollection Date: 2022-04-29

Saad Nasir, Saqib Raza Khan, Rodaba Iqbal, Alizah Pervaiz Hashmi, Munira Moosajee, Noreen Nasir

Background and aim: Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome that is induced by hyper-activated macrophages, cytotoxic T cells, and reduced natural killer cell activity. A 46-year-old gentleman presented to us with complaints of intermittent fever for the past 2 weeks associated with fatigue along with oral ulcers and skin rashes which resolved spontaneously. These symptoms started after he received the second dose of the BBIP-CorV COVID-19 vaccine. His complete blood picture showed pancytopenia. A detailed infectious disease workup was unrevealing; however, his bone marrow biopsy revealed increased histiocyte activity, with some showing hemophagocytosis and dysplasia. Immunohistochemistry profile demonstrated strong CD 68 positivity. Further investigations showed raised serum ferritin and fasting triglyceride levels. He was immediately started on dexamethasone acetate at a dose of 10 mg/m², after which his clinical symptoms, as well as his blood parameters, improved remarkably. This is the first documented case in Pakistan.

Conclusion: The data from clinical trials support the general safety profile of inactivated COVID-19 vaccines. We endorse its mass implementation. However, we believe that robust data need to be generated to evidence any adverse events, especially those with serious outcomes. Physicians should be aware of inactivated COVID-19 vaccine as a possible trigger for HLH and start prompt treatment, resulting in favorable outcomes.

Relevance for patients: The presentation of HLH may vary and can present in an immunocompetent patient with no underlying risk factor. HLH should be kept in differentials when a patient presents with pancytopenia with a recent history of receiving COVID-19 vaccination. Steroids play a major role in the treatment of HLH, and definitive diagnosis and early treatment improve clinical outcomes.

背景和目的：噬血细胞性淋巴组织细胞增多症（HLH）是一种严重的高炎症综合征，由过度活化的巨噬细胞、细胞毒性T细胞和自然杀伤细胞活性降低引起。一位46岁的男士向我们提出了过去两周的间歇性发烧，并伴有疲劳，口腔溃疡和皮疹，这些症状自发消退。这些症状是在他接受第二剂BBIP-CorV COVID-19疫苗后开始的。他的全血图显示全血细胞减少。详细的传染病检查并没有揭示问题；然而，他的骨髓活检显示组织细胞活性增加，一些显示噬血细胞增多和发育不良。免疫组化示cd68阳性。进一步的调查显示血清铁蛋白和空腹甘油三酯水平升高。患者立即开始服用剂量为10mg /m2的醋酸地塞米松，此后他的临床症状和血液参数显著改善。这是巴基斯坦首次记录在案的病例。结论：临床试验数据支持COVID-19灭活疫苗的总体安全性。我们赞同它的大规模执行。然而，我们认为需要生成可靠的数据来证明任何不良事件，特别是那些严重后果的不良事件。医生应该意识到灭活的COVID-19疫苗可能引发HLH，并及时开始治疗，从而获得良好的结果。与患者的相关性：HLH的表现可能各不相同，并且可能出现在没有潜在危险因素的免疫功能正常的患者中。当患者出现全血细胞减少症且近期接种过COVID-19疫苗时，应保持HLH的差异。类固醇在治疗HLH中起主要作用，明确的诊断和早期治疗可改善临床结果。

{"title":"Inactivated COVID-19 vaccine triggering hemophagocytic lymphohistiocytosis in an immunocompetent adult - A case report.","authors":"Saad Nasir, Saqib Raza Khan, Rodaba Iqbal, Alizah Pervaiz Hashmi, Munira Moosajee, Noreen Nasir","doi":"","DOIUrl":"","url":null,"abstract":"Background and aim: Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome that is induced by hyper-activated macrophages, cytotoxic T cells, and reduced natural killer cell activity. A 46-year-old gentleman presented to us with complaints of intermittent fever for the past 2 weeks associated with fatigue along with oral ulcers and skin rashes which resolved spontaneously. These symptoms started after he received the second dose of the BBIP-CorV COVID-19 vaccine. His complete blood picture showed pancytopenia. A detailed infectious disease workup was unrevealing; however, his bone marrow biopsy revealed increased histiocyte activity, with some showing hemophagocytosis and dysplasia. Immunohistochemistry profile demonstrated strong CD 68 positivity. Further investigations showed raised serum ferritin and fasting triglyceride levels. He was immediately started on dexamethasone acetate at a dose of 10 mg/m2, after which his clinical symptoms, as well as his blood parameters, improved remarkably. This is the first documented case in Pakistan.Conclusion: The data from clinical trials support the general safety profile of inactivated COVID-19 vaccines. We endorse its mass implementation. However, we believe that robust data need to be generated to evidence any adverse events, especially those with serious outcomes. Physicians should be aware of inactivated COVID-19 vaccine as a possible trigger for HLH and start prompt treatment, resulting in favorable outcomes.Relevance for patients: The presentation of HLH may vary and can present in an immunocompetent patient with no underlying risk factor. HLH should be kept in differentials when a patient presents with pancytopenia with a recent history of receiving COVID-19 vaccination. Steroids play a major role in the treatment of HLH, and definitive diagnosis and early treatment improve clinical outcomes.","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"8 2","pages":"152-155"},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic tightening of the cardia mucosa in gastroesophageal reflux disease: A case series of 120 patients up to 1-year follow-up. 胃食管反流病的内镜下贲门粘膜收紧：120例患者长达1年的随访。

Journal of clinical and translational research

Pub Date : 2022-03-01 eCollection Date: 2022-04-29

Zhenhua Li, Yongliang Li, Yue Wu, Mingyan Li, Zhaobin Yan, Shanwen Nie, Zhitao Liang, Bo Li, Peiwen Zhu, Peilin Cui, Qinsheng Zhang

Background and aim: A technique of endoscopic tightening of the cardia mucosa for the treatment of gastroesophageal reflux disease (GERD) was developed and its clinical efficacy was observed.

Methods: 120 patients with GERD who underwent endoscopic tightening surgery from December 2017 to December 2019 were included in this study. GERD-Q score and constitution type of patients were evaluated preoperatively and at 1 month, 3 months, 6 months, and 1 year after surgery. In addition, effectiveness and side effects of the procedure were graded based on gastroesophageal flap valve (GEFV) function.

Results: GERD-Q score of 1 month, 3 months, 6 months, and 1 year after surgery were significantly decreased (P<0.01) compared with preoperative score. There were no significant differences between GERD-Q score of 1 month, 3 months, 6 months, and 1 year after surgery. The surgery proves to be effective in all GEFV grades, especially in Hill-III.

Conclusion: Endoscopic tightening is an effective method for the treatment of patients with GERD, especially of Hill-III patients. Attention should be paid to cardia width, ligation ring depth, and ring number during operation.

Relevance for patients: ETCM is a safe endoscopic procedure with minimal trauma, which has been proved effective for patients who are diagnosed with GERD.

背景与目的：介绍一种内镜下贲门粘膜收紧术治疗胃食管反流病的方法，并观察其临床疗效。方法：本研究纳入2017年12月至2019年12月行内镜收紧手术的120例胃食管反流患者。术前及术后1个月、3个月、6个月、1年对患者的GERD-Q评分和体质类型进行评价。此外，根据胃食管瓣（GEFV）功能对手术的有效性和副作用进行分级。结果：术后1个月、3个月、6个月、1年的GERD- q评分均显著降低(p)。结论：内镜收紧术是治疗胃食管反流的有效方法，尤其是Hill-III型患者。术中应注意心宽、结扎环深度、结扎环数。与患者的相关性：ETCM是一种安全的内镜手术，创伤最小，已被证明对诊断为胃食管反流的患者有效。

{"title":"Endoscopic tightening of the cardia mucosa in gastroesophageal reflux disease: A case series of 120 patients up to 1-year follow-up.","authors":"Zhenhua Li, Yongliang Li, Yue Wu, Mingyan Li, Zhaobin Yan, Shanwen Nie, Zhitao Liang, Bo Li, Peiwen Zhu, Peilin Cui, Qinsheng Zhang","doi":"","DOIUrl":"","url":null,"abstract":"Background and aim: A technique of endoscopic tightening of the cardia mucosa for the treatment of gastroesophageal reflux disease (GERD) was developed and its clinical efficacy was observed.Methods: 120 patients with GERD who underwent endoscopic tightening surgery from December 2017 to December 2019 were included in this study. GERD-Q score and constitution type of patients were evaluated preoperatively and at 1 month, 3 months, 6 months, and 1 year after surgery. In addition, effectiveness and side effects of the procedure were graded based on gastroesophageal flap valve (GEFV) function.Results: GERD-Q score of 1 month, 3 months, 6 months, and 1 year after surgery were significantly decreased (P<0.01) compared with preoperative score. There were no significant differences between GERD-Q score of 1 month, 3 months, 6 months, and 1 year after surgery. The surgery proves to be effective in all GEFV grades, especially in Hill-III.Conclusion: Endoscopic tightening is an effective method for the treatment of patients with GERD, especially of Hill-III patients. Attention should be paid to cardia width, ligation ring depth, and ring number during operation.Relevance for patients: ETCM is a safe endoscopic procedure with minimal trauma, which has been proved effective for patients who are diagnosed with GERD.","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"8 2","pages":"147-151"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach. 通过分子对接和分子动力学模拟方法重新利用扁平苔藓药物作为潜在的抗COVID-19治疗药物。

Journal of clinical and translational research

Pub Date : 2022-03-01 eCollection Date: 2022-04-29

Unnati Soni, Pratyush Singh, Om Prakash Gupta, Shalini Gupta, Saurabh Pratap Singh, Prerna Singh, Sangeeta Singh, Krishna Mishra

Background and aim: The present study intends to investigate COVID-19 by targeting their main proteins with 17 selected drugs used for treating Oral Lichen Planus (OLP) which is a chronic muco-cutaneous disorder. Here, an attempt is made to gain better insight into the structure of various drugs targeting specific proteins which will be helpful in developing drugs useful for therapeutic and preventive measures.

Method: In silico studies, molecular docking and molecular dynamic simulations were performed to repurpose the therapeutic drugs (n = 17) which were used to treat OLP against COVID-19. In addition, the maximum binding affinities of the key protein spike glycoprotein, main-protease (M^pro) of coronavirus, and Angiotensin-Converting Enzyme-2 (ACE-2) in the human body were evaluated with the selected drugs.

Results: Epigallocatechin-3-gallate (EGCG) showed the highest docking values among the drugs selected for repurposing. Among the target proteins, EGCG has shown maximum binding affinity with ACE-2 receptor. Further, according to the molecular dynamic simulation studies, EGCG has shown the least conformational fluctuations with M^pro.

Conclusion: EGCG can be a potential inhibitor drug which can bind with ACE-2 receptor thus inhibiting the interaction of mainly M^pro protein and spike glycoprotein of SARS-CoV-2.

Relevance for patients: EGCG, a natural compound shows antiviral potential having considerably high affinity and stability with SARS-CoV-2. It might be further employed as a lead drug against selective inhibitors of SARS-CoV-2 for the therapeutic management of COVID-19 patients after necessary clinical trials.

背景与目的：本研究拟选择17种治疗口腔扁平苔藓（OLP）的药物，以其主要蛋白为靶点，对新型冠状病毒（COVID-19）进行研究。在这里，我们试图更好地了解针对特定蛋白质的各种药物的结构，这将有助于开发用于治疗和预防措施的药物。方法：通过计算机研究、分子对接和分子动力学模拟等方法，对17例OLP治疗药物进行重新定位。此外，用所选药物评估了冠状病毒关键蛋白刺突糖蛋白、冠状病毒主要蛋白酶（Mpro）和血管紧张素转换酶-2 （ACE-2）在人体内的最大结合亲和力。结果：表没食子儿茶素-3-没食子酸酯（EGCG）在选择的再利用药物中对接值最高。在靶蛋白中，EGCG与ACE-2受体的结合亲和力最大。此外，根据分子动力学模拟研究，EGCG与Mpro的构象波动最小。结论：EGCG可能是一种潜在的抑制药物，可与ACE-2受体结合，从而抑制SARS-CoV-2主要Mpro蛋白和刺突糖蛋白的相互作用。与患者的相关性：EGCG是一种天然化合物，具有抗病毒潜力，对SARS-CoV-2具有相当高的亲和力和稳定性。经过必要的临床试验，它可能进一步作为抗SARS-CoV-2选择性抑制剂的先导药物用于COVID-19患者的治疗管理。

{"title":"Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach.","authors":"Unnati Soni, Pratyush Singh, Om Prakash Gupta, Shalini Gupta, Saurabh Pratap Singh, Prerna Singh, Sangeeta Singh, Krishna Mishra","doi":"","DOIUrl":"","url":null,"abstract":"Background and aim: The present study intends to investigate COVID-19 by targeting their main proteins with 17 selected drugs used for treating Oral Lichen Planus (OLP) which is a chronic muco-cutaneous disorder. Here, an attempt is made to gain better insight into the structure of various drugs targeting specific proteins which will be helpful in developing drugs useful for therapeutic and preventive measures.Method: In silico studies, molecular docking and molecular dynamic simulations were performed to repurpose the therapeutic drugs (n = 17) which were used to treat OLP against COVID-19. In addition, the maximum binding affinities of the key protein spike glycoprotein, main-protease (Mpro) of coronavirus, and Angiotensin-Converting Enzyme-2 (ACE-2) in the human body were evaluated with the selected drugs.Results: Epigallocatechin-3-gallate (EGCG) showed the highest docking values among the drugs selected for repurposing. Among the target proteins, EGCG has shown maximum binding affinity with ACE-2 receptor. Further, according to the molecular dynamic simulation studies, EGCG has shown the least conformational fluctuations with Mpro.Conclusion: EGCG can be a potential inhibitor drug which can bind with ACE-2 receptor thus inhibiting the interaction of mainly Mpro protein and spike glycoprotein of SARS-CoV-2.Relevance for patients: EGCG, a natural compound shows antiviral potential having considerably high affinity and stability with SARS-CoV-2. It might be further employed as a lead drug against selective inhibitors of SARS-CoV-2 for the therapeutic management of COVID-19 patients after necessary clinical trials.","PeriodicalId":94073,"journal":{"name":"Journal of clinical and translational research","volume":"8 2","pages":"127-146"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of clinical and translational research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀